These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 10796051)

  • 21. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?
    Staib L; Schirrmeister H; Reske SN; Beger HG
    Am J Surg; 2000 Jul; 180(1):1-5. PubMed ID: 11036130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of resectable recurrences in colorectal cancer patients with 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
    Peng NJ; Hu C; King TM; Chiu YL; Wang JH; Liu RS
    Cancer Biother Radiopharm; 2013; 28(6):479-87. PubMed ID: 23713869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.
    Ruers TJ; Langenhoff BS; Neeleman N; Jager GJ; Strijk S; Wobbes T; Corstens FH; Oyen WJ
    J Clin Oncol; 2002 Jan; 20(2):388-95. PubMed ID: 11786565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
    Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
    Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas.
    Lucas JD; O'Doherty MJ; Wong JC; Bingham JB; McKee PH; Fletcher CD; Smith MA
    J Bone Joint Surg Br; 1998 May; 80(3):441-7. PubMed ID: 9619933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
    Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
    Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic accuracy of CE-CT, MRI and FDG PET/CT for detecting colorectal cancer liver metastases in patients considered eligible for hepatic resection and/or local ablation.
    Sivesgaard K; Larsen LP; Sørensen M; Kramer S; Schlander S; Amanavicius N; Bharadwaz A; Tønner Nielsen D; Viborg Mortensen F; Morre Pedersen E
    Eur Radiol; 2018 Nov; 28(11):4735-4747. PubMed ID: 29736846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer.
    Flanagan FL; Dehdashti F; Ogunbiyi OA; Kodner IJ; Siegel BA
    Ann Surg; 1998 Mar; 227(3):319-23. PubMed ID: 9527052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [F-18 fluorodeoxyglucose positron emission tomography in colorectal carcinoma].
    Jörg L; Langsteger W
    Wien Med Wochenschr; 2002; 152(11-12):276-9. PubMed ID: 12138655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 18F-FDG PET/CT superior to serum CEA in detection of colorectal cancer and its recurrence.
    Makis W; Kurzencwyg D; Hickeson M
    Clin Imaging; 2013; 37(6):1094-7. PubMed ID: 23993799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDG-PET improves the management of patients with suspected recurrence of colorectal cancer.
    Simó M; Lomeña F; Setoain J; Pérez G; Castellucci P; Costansa JM; Setoain-Quinquer J; Doménech-Torné F; Carrió I
    Nucl Med Commun; 2002 Oct; 23(10):975-82. PubMed ID: 12352596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer.
    Flamen P; Stroobants S; Van Cutsem E; Dupont P; Bormans G; De Vadder N; Penninckx F; Van Hoe L; Mortelmans L
    J Clin Oncol; 1999 Mar; 17(3):894-901. PubMed ID: 10071281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Imaging in the diagnosis of colorectal liver metastases and extrahepatic abnormalities].
    Bipat S; van Leeuwen MS; Oyen WJ; Planting AS; IJzermans JN; Stoker J
    Ned Tijdschr Geneeskd; 2008 Apr; 152(15):857-62. PubMed ID: 18512524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
    Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
    Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.
    Abdel-Nabi H; Doerr RJ; Lamonica DM; Cronin VR; Galantowicz PJ; Carbone GM; Spaulding MB
    Radiology; 1998 Mar; 206(3):755-60. PubMed ID: 9494497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.
    Sun SS; Chen TC; Yen RF; Shen YY; Changlai SP; Kao A
    Anticancer Res; 2001; 21(4B):2957-61. PubMed ID: 11712793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of low dose (18)F-FDG PET-CT in patients with suspected colorectal carcinoma recurrence in conventional diagnostic methods.
    Ochoa-Figueroa MA; Uña-Gorospe J; Allende-Riera A; Cárdenas-Negro JC; Muñoz-Iglesias J; Cabello-García D; De Sequera-Rahola M; Martínez-Gimeno E
    Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):249-56. PubMed ID: 23067526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of FDG PET-CT on the detection of extrahepatic disease in patients being considered for resection of colorectal liver metastasis.
    Lake ES; Wadhwani S; Subar D; Kauser A; Harris C; Chang D; Lapsia S
    Ann R Coll Surg Engl; 2014 Apr; 96(3):211-5. PubMed ID: 24780786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases.
    Georgakopoulos A; Pianou N; Kelekis N; Chatziioannou S
    Clin Imaging; 2013; 37(3):536-41. PubMed ID: 23116727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.